

NEXT GENERATION DRUG FOR PARKINSON DISEASE

Innovative therapeutic peptides against Parkinson's disease


ERG\NEO

L'AVENIR EST FAIT D'AUDACE

PRESENTATION

Around 6 million people are suffering from Parkinson disease worldwide. ; In the US, cost is about \$23 billion per year. There is no cure, actual treatments are helping relieve the symptoms and maintain in certain level the patient quality of life : L-DOPA/ DOPA agonists ; COMT & MAO inhibitors have lack of efficiency and significant side effects. LRRK2 phosphorylation has an important effect in PD pathogenesis. We propose a new therapeutic peptides which targets PP1/ LRRK2 interaction, allowing the manipulation of PP1 effect on LRRK2.

Parkinson's Disease - Interfering peptides - PP1 - LRRK2
Cell penetrating and interfering peptides



Parkinson's Disease
Credit : Medindia.net

COMPETITIVE ADVANTAGES

- Less cost than a biological molecule such as mAb.
- Low toxicity due to the fact that degradation of a peptide generates amino acids.
- Low immunogenicity since the size of the peptide is short and, as a consequence, lower possibility of stimulate the immune system.
- Blood Brain Barrier (BBB) penetration due to the association of the interfering peptide to a shuttle that cross the BBB.

PUBLICATIONS

Identification peptides interfering with the LRRK2/ PP1 interaction (accepted in PlosOne)

APPLICATIONS

- Parkinson's Disease

INTELLECTUAL PROPERTY

Patent application filed on March 2019.

CONTACT

+33 (0)1 44 23 21 50
industriels@erganeo.com
Ref. project : 542

DEVELOPMENT PHASE

- ☑ In vitro and in vivo testing in process.